Qube Research & Technologies (QRT)’s Aspen Aerogels ASPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-126,275
Closed -$879K 3665
2025
Q3
$879K Sell
126,275
-129,319
-51% -$912K ﹤0.01% 2570
2025
Q2
$1.51M Sell
255,594
-172,990
-40% -$995K ﹤0.01% 2305
2025
Q1
$2.74M Sell
428,584
-354,651
-45% -$3.42M ﹤0.01% 1836
2024
Q4
$9.3M Buy
783,235
+769,377
+5,552% +$13.1M 0.01% 1139
2024
Q3
$384K Sell
13,858
-195,459
-93% -$4.89M ﹤0.01% 2352
2024
Q2
$4.99M Buy
+209,317
New +$4.91M 0.01% 1254
2024
Q1
Sell
-13,040
Closed -$206K 4449
2023
Q4
$206K Buy
+13,040
New +$135K ﹤0.01% 2779
2023
Q2
Sell
-46,642
Closed -$347K 2376
2023
Q1
$347K Buy
+46,642
New +$464K ﹤0.01% 1694
2022
Q2
Sell
-33,111
Closed -$1.14M 2474
2022
Q1
$1.14M Buy
+33,111
New +$1.07M 0.01% 1104
2020
Q2
Sell
-68,250
Closed -$419K 1703
2020
Q1
$419K Buy
68,250
+26,850
+65% +$218K 0.02% 623
2019
Q4
$321K Buy
+41,400
New +$286K 0.01% 1191

Other funds holding ASPN

Qube Research & Technologies (QRT)'s ASPN Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of Aspen Aerogels (ASPN) in Q4 2025, closing a stake of 126,275 shares — an estimated $879K sold.

Qube Research & Technologies (QRT) first reported a position in ASPN in Q4 2019 and held it in 11 quarters. The position peaked at $9.3M in Q4 2024. 183 funds tracked by Wall St. Rank hold ASPN as of Q4 2025.

  • Qube Research & Technologies (QRT) reported no remaining Aspen Aerogels position as of Q4 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 126,275 Aspen Aerogels shares in Q4 2025, an estimated $879K.
  • Qube Research & Technologies (QRT) first reported a position in Aspen Aerogels in Q4 2019 and held it in 11 quarters.
  • Qube Research & Technologies (QRT)'s Aspen Aerogels position peaked at $9.3M in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Aspen Aerogels as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.